Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 23;11(6):1016.
doi: 10.3390/vaccines11061016.

DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond

Joel N Maslow  1   2 , Ijoo Kwon  1 , Sagar B Kudchodkar  1 , Deborah Kane  1 , Amha Tadesse  1 , Hyojin Lee  1 , Young K Park  1 , Kar Muthumani  1 , Christine C Roberts  1
Affiliations

DNA Vaccines for Epidemic Preparedness: SARS-CoV-2 and Beyond

Joel N Maslow et al. Vaccines (Basel). .

Abstract

We highlight the significant progress in developing DNA vaccines during the SARS-CoV-2 pandemic. Specifically, we provide a comprehensive review of the DNA vaccines that have progressed to Phase 2 testing or beyond, including those that have received authorization for use. DNA vaccines have significant advantages with regard to the rapidity of production, thermostability, safety profile, and cellular immune responses. Based on user needs and cost, we compare the three devices used in the SARS-CoV-2 clinical trials. Of the three devices, the GeneDerm suction device offers numerous benefits, particularly for international vaccination campaigns. As such, DNA vaccines represent a promising option for future pandemics.

Keywords: DNA vaccine; SARS-CoV-2; suction-mediated DNA transfection; vaccine thermostability.

PubMed Disclaimer

Conflict of interest statement

Authors are employees of GeneOne Life Science, Inc. Y.K.P. and J.N.M. own stock or stock options with a value in excess of USD 10,000.

References

    1. Chavda V.P., Pandya R., Apostolopoulos V. DNA vaccines for SARS-CoV-2: Toward third-generation vaccination era. Expert Rev. Vaccines. 2021;20:1549–1560. doi: 10.1080/14760584.2021.1987223. - DOI - PMC - PubMed
    1. Shafaati M., Saidijam M., Soleimani M., Hazrati F., Mirzaei R., Amirheidari B., Tanzadehpanah H., Karampoor S., Kazemi S., Yavari B., et al. A brief review on DNA vaccines in the era of COVID-19. Future Virol. 2022;17:1. doi: 10.2217/fvl-2021-0170. - DOI - PMC - PubMed
    1. Momin T., Kansagra K., Hardik Patel H., Sunil Sharma S., Sharma B., Patel J., Tanzadehpanah H., Karampoor S., Kazemi S., Yavari B., et al. Safety and Immunogenicity of a DNA SARS-CoV-2 vaccine (ZyCoV-D): Results of an open-label, non-randomized phase I part of phase I/II clinical study by intradermal route in healthy subjects in India. EClinicalMedicine. 2021;38:101020. doi: 10.1016/j.eclinm.2021.101020. - DOI - PMC - PubMed
    1. Khobragade A., Bhate S., Ramaiah V., Deshpande S., Giri K., Phophle H., Supe P., Godara I., Revanna R., Nagarkar R., et al. Efficacy, safety, and immunogenicity of the DNA SARS-CoV-2 vaccine (ZyCoV-D): The interim efficacy results of a phase 3, randomised, double-blind, placebo-controlled study in India. Lancet. 2022;399:1313–1321. doi: 10.1016/S0140-6736(22)00151-9. - DOI - PMC - PubMed
    1. Mammen M.P., Tebas P., Agnes J., Giffear M., Kraynyak K., Blackwood E., Amante D., Reuschel E.L., Purwar M., Christensen-Quick A., et al. Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: A preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure. medRxiv. 2021 doi: 10.1101/2021.05.07.21256652. - DOI